Coagulation factor V (FV) is an essential component of the prothrombinase complex, which activates the zymogen prothrombin to thrombin. Acquired FV inhibitor is rare and clinical symptoms are quite variable. The aim of this study was to summarize the spectrum of the bleeding presentation of acquired FV deficiency and characterize the underlying causes of the clinical symptoms. This study was designed as a descriptive retrospective and 30 case reports were included for further analysis. At least 33 cases of acquired FV inhibitor were investigated. Most patients have a presentation of bleeding and most of those are from hematuria and bleeding at surgical sites. Seven cases of asymptomatic acquired FV inhibitor were also detected. A total of 39.4% (19 of 33) of those cases with acquired FV inhibitor have an unknown cause. For those with known etiologies, chemical and drug-induced causes are the most common (30.8%).
[Show abstract][Hide abstract] ABSTRACT: Acquired inhibitor of coagulation factor V is a rare clinical condition and may cause significant morbidity and mortality. We report here the first Korean case of acquired isolated factor V inhibitor developed in a 73-year-old male patient after surgery for pancreatic head carcinoma. At post-operation day 2, intra-abdominal bleeding was recognized that was associated with a prolonged prothrombin time and activated partial thromboplastin time. The prolongation of both conditions was not corrected by a mixing test and factor V activity was reported to be 2%. Quantified titers of inhibitors were increased from 3.5 Bethesda unit to 8.4 Bethesda unit during follow-up analysis. In spite of the treatment with steroids and intravenous immunoglobulins, the case ended fatally. When acquired bleeding tendency with prolonged coagulation screening test is observed, evaluation of inhibitors of coagulation factors may be essential for the diagnosis and following appropriate management of the condition.
The Korean journal of hematology 01/2008; 43(3). DOI:10.5045/kjh.2008.43.3.190
[Show abstract][Hide abstract] ABSTRACT: Rituximab has already been successfully used to treat immune-mediated bleeding disorders such as acquired factor VIII inhibitor. We report here a case of severe acquired factor V (FV) inhibitor deficiency due to FV inhibitor which has been dramatically improved after rituximab.
American Journal of Hematology 02/2008; 83(2):163-4. DOI:10.1002/ajh.21056 · 3.80 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.